Eu Yan Sang Singapore

Rohto and Mitsui Acquire Eu Yan Sang for $695M: A Game-Changing Deal

Rohto and Mitsui make a groundbreaking move in the acquisition of Eu Yan Sang, shaking up the healthcare industry!

In a strategic move, Rohto and Mitsui have taken the lead in acquiring Eu Yan Sang, a well-known healthcare brand in Singapore. The consortium successfully purchased an 86% stake in Eu Yan Sang from Righteous Crane Holding (RCH), marking a significant development in the industry landscape. RCH, an investment holding company, is under the ownership of Tower Capital Asia subsidiary. This acquisition is set to bring about substantial changes in the future direction of Eu Yan Sang and position Rohto and Mitsui as key players in the healthcare market.

With Rohto and Mitsui at the helm, Eu Yan Sang is expected to undergo strategic transformations and expansions. The expertise and capital injection from these renowned companies are likely to propel Eu Yan Sang to new heights of success. The collaboration between Rohto, Mitsui, and Eu Yan Sang is anticipated to bring innovative healthcare solutions and products to the forefront, catering to the evolving needs of consumers in Singapore and beyond.

Eu Yan Sang's acquisition by Rohto and Mitsui underscores a shift in the dynamics of the healthcare sector. This bold move not only consolidates the position of these industry giants but also sets a new benchmark for acquisitions in the region. As Eu Yan Sang ventures into a new chapter under the leadership of Rohto and Mitsui, the industry awaits with bated breath to witness the innovative strategies and developments that will emerge from this game-changing acquisition.